EUVIMEDEUVIMED entdecken
Crossref

Ferroptosis‐Driven Anticancer Activity of 1,3,4‐Oxadiazole–Benzimidazole/Acetamide Hybrids: Design, Synthesis, and Biological Profiling

Fatma Fouad Hagar, Amer Ali Abd El-Hafeez iD, Samar H Abbas iD, Ahmed M Sayed, Asim Abdelfattah, Heba S Abd-Ellah, Dalia Abdelhamid, Mohamed Abdel-Aziz

Archiv der Pharmazie · 2026-03 · 359 (3)

DOI: 10.1002/ardp.70229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 24.03.2026. Verfasst von Fatma Fouad Hagar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia, Egypt. Hauptthemen laut MEDLINE: Benzimidazoles, Antineoplastic Agents, Oxadiazoles, Drug Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of 1,3,4‐oxadiazole‐benzimidazole/acetamide derivatives ( 7a–r ) was designed, synthesized, and evaluated for their anticancer activity. NCI‐screening results at 10 µM against the 60 human tumor cell line panel revealed a broad‐spectrum of antiproliferative effects of the tested compounds. Compounds 7b , 7e , 7f , 7g , 7h , 7k , 7l , and 7r were further tested in a five‐dose assay, and they exhibited half‐maximal growth inhibitory (GI 50 ) values ranging from 0.90 to 43.50 µM. Focused studies in MDA‐MB‐231 triple‐negative breast cancer (TNBC) cells demonstrated that compounds 7b , 7g , 7h , 7k , and 7l possessed potent antiproliferative activity, with half‐maximal inhibitory concentration (IC 50 ) values between 1.92 and 3.69 µM. Mechanistic investigations using cell death pathway inhibitors indicated that compounds 7b , 7k , and 7l did not induce necrosis, apoptosis, or autophagy. Instead, these compounds significantly increased intracellular ferrous iron (Fe 2+ ) and malondialdehyde (MDA) levels and induced lipid peroxidation in MDA‐MB‐231 cells. In parallel, GPX4 expression was markedly reduced at both the mRNA and protein levels, supporting ferroptosis as the primary mechanism of action. In addition, molecular docking studies and molecular dynamics simulations were performed for derivatives 7b , 7k , and 7l in order to confirm the mechanistic study. Collectively, these findings suggest that the 1,3,4‐oxadiazole–benzimidazole/acetamide scaffold represents a promising chemotype for developing ferroptosis‐inducing therapeutics targeting TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesAntineoplastic AgentsOxadiazolesDrug DesignAcetamidesFerroptosisHumansStructure-Activity RelationshipCell ProliferationDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, DrugMolecular Docking SimulationCell Line, TumorMDA-MB-231 CellsLipid Peroxidation

Stichwörter der Autor:innen

1,3,4‐oxadiazoleantiproliferativebenzimidazoleferroptosisglutathione peroxidase 4 (GPX4)

Substanzen

BenzimidazolesAntineoplastic AgentsOxadiazoles1,3,4-oxadiazoleAcetamidesacetamide

Autor:innen und Institutionen

  • Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia, Egypt.
  • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Minia National University, New Minia, Egypt.
  • Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.
  • Department of Pharmacognosy, Collage of Pharmacy, Almaaqal University, Basrah, Iraq.
  • Department of Neuroscience and Experimental Therapeutics, Texas A&M University Health Science Center, Bryan, Texas, USA.

ORCID-Profile: Amer Ali Abd El-Hafeez, Samar H Abbas

Zitieren

APA

Hagar, F. F., Abd El-Hafeez, A. A., Abbas, S. H., Sayed, A. M., Abdelfattah, A., Abd-Ellah, H. S., Abdelhamid, D., & Abdel-Aziz, M. (2026). Ferroptosis‐Driven Anticancer Activity of 1,3,4‐Oxadiazole–Benzimidazole/Acetamide Hybrids: Design, Synthesis, and Biological Profiling. Archiv der Pharmazie, 359(3). https://doi.org/10.1002/ardp.70229

Vancouver

Hagar FF, Abd El-Hafeez AA, Abbas SH, Sayed AM, Abdelfattah A, Abd-Ellah HS, et al. Ferroptosis‐Driven Anticancer Activity of 1,3,4‐Oxadiazole–Benzimidazole/Acetamide Hybrids: Design, Synthesis, and Biological Profiling. Archiv der Pharmazie. 2026;359(3). doi:10.1002/ardp.70229

BibTeX
@article{Hagar2026,
  author = {Hagar, Fatma Fouad and Abd El-Hafeez, Amer Ali and Abbas, Samar H and Sayed, Ahmed M and Abdelfattah, Asim and Abd-Ellah, Heba S and Abdelhamid, Dalia and Abdel-Aziz, Mohamed},
  title = {Ferroptosis‐Driven Anticancer Activity of 1,3,4‐Oxadiazole–Benzimidazole/Acetamide Hybrids: Design, Synthesis, and Biological Profiling},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {3},
  doi = {10.1002/ardp.70229}
}
Kostenlos starten →